09:20am Wednesday 16 October 2019

Pioneering Artificial Pancreas, Developed at UVA, to Undergo Final Tests

Favorable results from these long-term clinical trials examining how the artificial pancreas works in real-life settings could lead the U.S. Food and Drug Administration and other international regulatory groups to approve the device for use by people with type 1 diabetes, whose bodies do not produce enough insulin. Approximately 1.25 million Americans have type 1 diabetes, according to the U.S. Centers for Disease Control and Prevention.

The trials will be conducted at nine locations in the U.S. and Europe, supported by a grant of more than $12.6 million from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. The first study – the International Diabetes Closed-Loop trial – will test technology developed at UVA by a research team led by Boris Kovatchev, director of the UVA Center for Diabetes Technology. That technology has been further refined for clinical use by TypeZero Technologies, a startup company in Charlottesville that has licensed the UVA system.

Boris Kovatchev has worked with researchers at UVA and elsewhere to develop and refine the artificial pancreas, which will soon undergo human trials.

Boris Kovatchev has worked with researchers at UVA and elsewhere to develop and refine the artificial pancreas, which will soon undergo human trials.
The second trial will also examine a new control algorithm developed by the team of Dr. Francis Doyle III at the Harvard John A. Paulson School of Engineering and Applied Sciences to test whether it further improves control of blood-sugar levels.

“To be ultimately successful as an optimal treatment for diabetes, the artificial pancreas needs to prove its safety and efficacy in long-term pivotal trials in the patient’s natural environment,” Kovatchev said. “Our foremost goal is to establish a new diabetes treatment paradigm: the artificial pancreas is not a single-function device; it is an adaptable, wearable network surrounding the patient in a digital treatment ecosystem.”

The goal of the artificial pancreas is to eliminate the need for people with type 1 diabetes to stick their fingers multiple times daily to check their blood-sugar levels and to inject insulin manually.

Instead, the artificial pancreas is designed to oversee and adjust insulin delivery as needed. At the center of the artificial pancreas platform – known as InControl – is a reconfigured smartphone running advanced algorithms that is linked wirelessly to a blood-sugar monitor and an insulin pump that the patient wears, as well as a remote-monitoring site. People with the artificial pancreas can also access assistance via telemedicine.

Two trials are planned as part of the NIH-funded study. In the first study, 240 patients with type 1 diabetes will test the safety and effectiveness of the artificial pancreas for six months while going about their regular daily routines. The artificial pancreas will be compared with a standard insulin pump on two key measures: how well blood-sugar levels are controlled and whether the risk of hypoglycemia, or low blood sugar, is reduced.

A second trial will follow 180 patients who completed the first study for an additional six months to test the Harvard University-developed algorithm and determine whether it further enhances blood sugar control.

Along with UVA, the artificial pancreas will be tested at eight additional sites: Harvard University in Boston; the Icahn School of Medicine at Mount Sinai in New York; the Mayo Clinic in Rochester, Minnesota; the University of Colorado; Stanford University; the University of Montpellier in France; the University of Padova in Italy; and the Academic Medical Center at the University of Amsterdam in The Netherlands.

The NIH/NIDDK grant is No. UC4DK108483.

Media Contact

Eric Swensen

U.Va. Health System

ews3j@virginia.edu 434-924-5770

Share on:

MORE FROM Drugs Approvals and Trials

Health news